Propensity scores for receipt of anti-TNF vs. non anti-TNF therapy will be constructed based upon a priori and empirically-derived covariates that will include number of prior biologic used, concomitant MTX, concomitant glucocorticoid use/dose, duration of RA, and reason for previous biologic discontinuation (primary vs. secondary non-response vs. safety/tolerability vs. other).
Another reason reason for the failure of previous studies on biomarkers for the onset of antidepressants' action might be that they were usually restricted to either one measurement (baseline) or two measurements with an interval of at least 4 weeks (e.g. before and after antidepressant treatment), reflecting the traditional view of a delayed onset of antidepressants' action.
That is one reason that creators of previous hits, like the teams behind shows like "The Office," "E.R".
Patients with an adverse event (AE) as their primary reason for discontinuation of previous VEGFr-TKI therapy were included.
The most frequent reason for discontinuation of previous therapy in patients with pre-treatment was inadequate response (N = 216, 61.9%).
The most frequent reason for discontinuation of previous treatment prior to entering the study was inadequate response (N = 216, 51.3%).
When assessed by reason for discontinuation of previous anti-TNF agent(s), however, AEs appeared to be more common among patients who had discontinued prior anti-TNF therapy because of intolerance than because of lack of efficacy or 'other' reasons.
This study was not powered to detect differences in efficacy based on type, number or reason for failure of previous anti-TNF therapy; therefore, statistical testing was not performed.
Patients for whom an AE was the primary reason for discontinuation of previous sunitinib therapy, sorafenib therapy or both (i.e., discontinuation of previous VEGFr-TKI therapy because of unacceptable toxicity) were included in this subgroup analysis and assessed for PFS and safety.
Patients were either methotrexate-naive or had previous exposure of 10 mg/week or less for 3 weeks or less, with none administered for 3 months before providing informed consent (there were no requirements relating to the reason for discontinuation of previous methotrexate therapy).
